Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight increase in stock price and trading volume, with significant financing activities on February 25, indicating investor interest despite a net financing outflow [1] - On February 25, He Yuan Bio's stock rose by 2.20%, with a trading volume of 87.85 million yuan, and a net financing outflow of 1.42 million yuan, resulting in a total financing and securities balance of 252 million yuan [1] - The company specializes in the research, production, and sales of plant-derived human serum albumin and other products, with 75.44% of its revenue coming from recombinant human albumin [1] Group 2 - As of October 28, He Yuan Bio had 47,100 shareholders, a significant increase of 84,075% compared to the previous period, while the average number of circulating shares per person decreased by 99.85% [2] - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million yuan, a decline of 8.44% year-on-year [2]
禾元生物2月25日获融资买入737.24万元，融资余额2.52亿元